Sign In
Buy GHRS
$23.61
+1.52 (+6.88%)
At Close: Jun 23, 2026
GH Research Announces Publication of Phase 2a Postpartum Depression Results
07:00am, Thursday, 04'th Jun 2026
DUBLIN, June 04, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS) today announced the publication of the full results from its Phase 2a trial in postpartum depression (PPD) and the acceptance o
GH Research: Rapid Onset And Short Action Change The Treatment Paradigm
04:07am, Wednesday, 20'th May 2026
GH Research is advancing GH001, an inhalable mebufotenin therapy, in treatment-resistant depression. GH Research's Phase 2b data was strong, and a global Phase 3 program is expected in 2026. While the
These Analysts Revise Their Forecasts On GH Research After Q1 Results
10:58am, Friday, 15'th May 2026
GH Research PLC (NASDAQ:GHRS) reported a wider-than-expected loss for the first quarter on Thursday.
GH Research Reports First Quarter 2026 Financial Results and Provides Business Update
07:00am, Thursday, 14'th May 2026
Phase 2b results in TRD published in JAMA Psychiatry GH001-HV-106 study enrolment completed; doses selected for the global Phase 3 pivotal program of GH001 in TRD GH001-HV-109 US IND-opening study en
GH Research Announces Pricing of $117.5 Million Underwritten Offering
08:00am, Wednesday, 29'th Apr 2026
DUBLIN, April 29, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing
FTSE 100 Live: London stocks slide as aerospace and defence sector falls
09:48am, Tuesday, 21'st Apr 2026
FTSE 100 down 35 points at 10,574 Markets await confirmation of US-Iran talks UK bond eyes developments in Westminster AB Foods, British Land,...
GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness
09:00am, Monday, 20'th Apr 2026
DUBLIN, April 20, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing
Enveric BioSciences Surges Over 90%, Other Psychedelic Stocks Soar In Monday Pre-Market: What's Going On?
08:35am, Monday, 20'th Apr 2026
Psychedelic drug maker shares jumped in Monday pre-market after an order from President Donald Trump to speed up psychedelic drug reviews
Psychedelics stocks rise after Trump order expands research, access pathways
05:56am, Monday, 20'th Apr 2026
Shares of psychedelics-related stocks climbed in early trade on Monday after US president Donald Trump signed an executive order aimed at accelerating...
Comparing Prenetics Global (NASDAQ:PRE) & GH Research (NASDAQ:GHRS)
04:27am, Wednesday, 15'th Apr 2026
Prenetics Global (NASDAQ: PRE - Get Free Report) and GH Research (NASDAQ: GHRS - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two busi
DUBLIN, March 25, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing
GH Research FY25 Results: Strong Cash Position As GH001 Advances Toward Phase 3
05:28pm, Tuesday, 10'th Mar 2026
GH Research PLC remains well-capitalized with $280.7 million in cash, supporting its lead candidate GH001 for Treatment-Resistant Depression. GHRS's investment thesis centers on replicating strong Pha
GH Research Reports Full Year 2025 Financial Results and Provides Business Update
07:00am, Thursday, 05'th Mar 2026
Completed Phase 2b trial of GH001 in TRD and presented the full dataset at the 2025 ASCP and ECNP congresses GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollment Cash
FDA Lifts Hold On GH Research's Depression Drug Trial After Two Years
09:37am, Monday, 05'th Jan 2026
The U.S. Food and Drug Administration (FDA) on Monday lifted the clinical hold on GH Research Plc's (NASDAQ: GHRS) Investigational New Drug Application (IND) for GH001.
GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026
07:00am, Monday, 05'th Jan 2026
GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollment Company to seek FDA alignment on global Phase 3 program replicating Phase 2b design Phase 3 initiation targeted f
